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Serum Cystatin C Is a Major Predictor of Vancomycin Clearance 
in a Population Pharmacokinetic Analysis of Patients with 
Normal Serum Creatinine Concentrations
We developed a population pharmacokinetic model of vancomycin by integrating the 
effects of cystatin C and other demographic factors in a large population of Korean 
patients with normal serum creatinine concentrations to elucidate the precise role of serum 
cystatin C concentrations in the prediction of vancomycin clearance. A population 
pharmacokinetic model of vancomycin was developed using NONMEM software from a 
total of 1,373 vancomycin concentration measurements in 678 patients whose serum 
creatinine concentrations were lower than 1.2 mg/dL. Covariate selection revealed that 
cystatin C was the most influential factor and had negative influence (−0.78) in the 
relationship. Total body weight, sex, age, and serum creatinine were also significantly 
correlated with the clearance. The estimated intersubject variabilities of clearance and 
volume of distribution were 24.7% and 25.1%, respectively. A 14-fold difference in 
predicted trough concentrations was observed according to only cystatin C concentrations 
in a population of simulated individuals with median demographic characteristics. The use 
of serum cystatin C as marker of vancomycin clearance for more accurate predictions of 
serum vancomycin concentrations could be useful, particularly among patients with 
normal serum creatinine concentrations.
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INTRODUCTION
Vancomycin is commonly used to treat methicillin-resistant 
Staphylococcus aureus (MRSA) infection, and its use has in-
creased with the prevalence of MRSA infection (1). Vancomycin 
has a narrow therapeutic range, and its concentration-effect 
and concentration-toxicity relationships are generally estab-
lished. Therefore, it is appropriate that the therapy is guided by 
therapeutic drug monitoring (TDM) (2, 3). Vancomycin is pri-
marily eliminated via the kidneys, and thus, renal function is an 
important factor in deciding the dosing regimen of vancomy-
cin. Serum creatinine (SCr) concentrations have been widely 
used as markers for renal function. However, SCr concentra-
tions may not accurately reflect the renal function in some pa-
tients such as elderly patients or those low muscle mass or my-
opathy. It leads to the overestimation of the glomerular filtra-
tion rate (GFR) represented by creatinine clearance, and the 
possibility of renal toxicity due to overdose would be increased 
in these cases (4, 5).
 Cystatin C is a low-molecular-weight protein that is stably 
produced in the body and has been proposed as an alternative 
endogenous marker of glomerular filtration. It is the product of 
a housekeeping gene expressed in all nucleated cells and there-
fore exhibits a stable production rate, even in the presence of an 
acute inflammatory response (6, 7), irrespective of muscle mass, 
gender, and body weight. Thus, cystatin C has many of the char-
acteristics of an ideal endogenous GFR marker. Recent investi-
gations have indicated that cystatin C may be superior to SCr as 
a GFR marker (6). Vancomycin clearance (CL) is better corre-
lated with cystatin C, especially in elderly or critically ill patients 
(8-10). Our previous study also found that vancomycin concen-
tration was better correlated with serum cystatin C than serum 
creatinine concentration in elderly patients (11). Although data 
from a small number of patients in the previous study were also 
included in this study, the purpose and methods of these two 
studies are significantly different from each other. The previous 
study was for simple correlation between vancomycin concen-
trations and two biomarkers (creatinine and cystatin C) of renal 
function in elderly patients. On the basis of the results of our 
previous study, we could plan for this population pharmacoki-
netics (PK) modeling study using cystatin C in general patient 
population.
 Although the role of cystatin C in vancomycin PK is estab-
lished, no validated population PK model to describe the over-
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all impact of cystatin C together with other demographic or clin-
ical sources of variability of vancomycin PK is available. If an in-
tegrated model with high predictive performance is developed, 
a more valuable basis for selecting a dosing regimen would be 
available. One reported study described a population PK ap-
proach with cystatin C in Japanese patients; however, this study 
only included data from 78 patients and only trough concentra-
tions, and analysis for other covariates and exact quantification 
of the cystatin C effect were limited (12). To develop an integrat-
ed model describing the effects of multiple factors and to clarify 
the precise impact of cystatin C, a sufficiently large population 
should be investigated. In addition, to avoid confounding ef-
fects and interactions between cystatin C and SCr, a population 
with normal SCr concentrations is optimal (≤ 1.2 mg/dL).
 Therefore, the present study attempted to develop an assump-
tion-free integrated population PK model of vancomycin to 
quantify the effects of various demographic factors including 
cystatin C on vancomycin PK by a nonlinear mixed effect mod-
eling approach in a large population of 678 Korean patients 
with normal SCr concentrations.
 
MATERIALS AND METHODS
Subjects and collection of blood samples
All data were collected from patients receiving vancomycin at a 
single institution from June 2006 to May 2010. We included pa-
tients who were aged 18 yr or older and those whose SCr con-
centrations were equal or lower than 1.2 mg/dL. Vancomycin 
concentrations had reached steady state in most patients. Van-
comycin was dispensed in 100 mL of saline per 1,000 mg and 
then intravenously infused over 1 hr. After vancomycin was ad-
ministered more than three times, its concentration was mea-
sured. The blood samplings were performed just before the next 
infusion (trough) and 1 hr after completing the infusion of van-
comycin (peak). Concentrations of SCr and cystatin C were mea-
sured on the same day with the vancomycin concentrations. 
Other clinical and demographic data were collected from the 
medical records of the recruited patients.
Assay of vancomycin, serum creatinine and cystatin C levels
The serum concentrations of vancomycin were determined us-
ing fluorescence polarization immunoassay methods (Cobas 
Integra 800 Analyzer, Roche, Mannheim, Germany). Serum cre-
atinine concentrations were measured using Jaffe kinetic meth-
od (Hitach 7600, Hitach, Tokyo, Japan). Reference ranges of SCr 
are 0.6-1.0 mg/dL for female and 0.8-1.3 mg/dL for male. There 
had been no change in standardization during the study period.
 Cystatin C concentrations were measured using particle en-
hanced immunoturbidimetric assay (Roche Cobas 6000, Roche, 
Mannheim, Germany). Human cystatin-C agglutinates with la-
tex particles coated with anti-cystatin C antibodies (rabbit). The 
aggregate is determined turbidimetrically at 546 nm. Reference 
ranges of cystatin C are 0.57-0.97 mg/L for female and 0.65-1.10 
mg/L for male. 
Population Pharmacokinetics analysis
The population PK model was built using the first-order con- 
ditional estimation with interaction method of the nonlinear 
mixed-effects modeling program NONMEM® (Version 7.1.0, 
Icon Development Solutions, Ellicott City, MD, USA) with the 
gfortran compiler. One- or two-compartment models were com-
pared, and several error models were investigated (i.e., propor-
tional, exponential, and additive random-effects models) to 
describe residual variability.
 The clinical and demographic variables analyzed as covari-
ates for potential influence on vancomycin PK were age, sex, 
total body weight (TBW), height, serum cystatin C concentra-
tion, SCr, intensive care unit admission, and concomitant use 
of amikacin or furosemide. To screen the influence of covari-
ates on parameter estimates, a graphic approach to exploratory 
data analysis and the generalized additive model (GAM) with 
the aid of Xpose4 were used (13). Potential covariates identified 
in the covariate screening step were then tested by stepwise 
forward selection and backward elimination using NONMEM 
and the PsN toolkit (14) on the criteria of the minimum objec-
tive function value (OFV; −2 × the log likelihood function) with 
significance set at P < 0.01 (forward) and P < 0.001 (backward).
 The final model was evaluated by goodness of fit plots be-
tween the predicted and observed values, performing a numer-
ical predictive check (NPC) and a bootstrap analysis using the 
PsN toolkit. The NPC generated 1,000 simulated concentration 
sets according to the final model, calculated the percentage of 
observations lying outside of their prediction intervals, and com-
pared the values with the expected number. The 95% confidence 
intervals for the expected number of observations lying outside 
their prediction intervals were also computed. The nonparamet-
ric bootstrap (15) analysis consisted of repeated 1,000 NONMEM 
runs with random sampling from the original data set. The boot-
strap median parameter values and 95% percentile intervals 
were compared with those estimated from the original data set 
using the final model. The predictive performance was evaluat-
ed by the mean prediction error (MPE, prediction error = ([pre- 
diction-observation]/observation) and mean absolute predic-
tion error (MAPE) of the population and individual predictions, 
which were measurements for bias and precision, respectively. 
The shrinkages of both empirical Bayes estimates (EBEs) and 
residual errors were calculated by 1−SD × (EBEs)/Intersubject 
variability, and 1−SD × individual weighted residual (IWRES), 
respectively.
 Finally, given the estimated parameter, simulations were per-
formed to describe the time course of the steady-state vanco-
mycin concentration profiles following the administration of 
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1,000 mg of vancomycin q 12 hr according to various cystatin C 
concentrations (0.4-3.0 mg/L) in a patient group having typical 
demographic characteristics or representative low and high 
clearance (CL) groups to depict how the covariate changes con-
tributed to the concentration profiles of vancomycin.
Ethics statement
This retrospective study was reviewed and approved by the in-
stitutional review board at Gangnam Severance Hospital of the 
Yonsei University Health System in Seoul, Korea (Reg. No. 3-2011- 
0106). The board waived the requirements to obtain informed 
consents. All procedures were conducted in accordance with 
the guidelines of the Declaration of Helsinki.
 
RESULTS
Clinical data description
Patient characteristics are listed in Table 1. A total of 1,373 van-
comycin concentration measurements in 678 patients were 
used to develop the model. The median vancomycin dosage 
was 2,000 mg/day, and most patients (89%) were treated with 
1,000-2,000 mg/day.
Population PK modeling
Both one- and two-compartment models were applied. OFV 
was lower in the two-compartment model; however, the covari-
ance step failed, and even minimization was terminated depend-
ing on the structure of intersubject variability (ISV) parameters. 
The parameter estimates were unrealistic for both the central 
and peripheral compartment volumes of distribution (36.5 and 
210 L, respectively) regardless of error model, revealing over-
parameterization probably because most of the data consisted 
of only one peak and one trough concentration per patient. In 
addition, simpler structural model would be more desirable for 
covariate model analysis (16). Therefore, the one-compartment 
model with zero-order intravenous input and first-order elimi-
nation was assumed to adequately describe serum vancomycin 
concentrations.
 The numbers of potential covariates detected by GAM analysis 
were seven for CL and five for V (volume of distribution). Using 
these potential covariates, stepwise covariate model searching 
was performed by forward selection and backward elimination. 
The final model was described by five covariates (age, TBW, 
cystatin C, SCr, and sex) for CL and three covariates (age, TBW, 
and sex) for V. We considered the creatinine clearance (CLCR) 
calculated by the Cockcroft and Gault method as a covariate, 
but this did not significantly improve OFV. The Cockcroft and 
Gault method also has components of creatinine concentration 
and demographic data, and thus, we omitted this variable to 
avoid a redundant covariate model structure. Cystatin C was 
found to be the most influential covariate, and it decreased OFV 
by 428.3. The relationship with CL was better described by a 
power model, and the rest of the variables had linear relation-
ships. The parameter values for the proposed final model are 
summarized in Table 2. In this model, the primary PK parame-
ters, CL and V, are expressed as follows:
 CL = 4.9 × (1 − 0.0042 × [age - 57]) × (1 + 0.00997 ×
               [TBW − 60.8]) × (1 − 0.322 × [SCr − 0.8]) × (cystatin 
                  C/0.91)−0.78 L/h  (if female, apply 0.85)
    V = 46.2 × (1 + 0.0058 × [age - 57]) × (1+ 0.00661 ×
               [TBW − 60.8]) L  (if female, apply 0.881).
 Compared to the base model, the estimated unexplained ISV 
of CL and V expressed as coefficients of variation (CVs) were 
Table 1. Characteristics of patients
Parameters Mean/No. Median Range
No. of patients 678
Sex (male/female) 400/278
Age (yr) 56 57 18-96
Body weight (kg) 62.3 60.8 27-140
Height (cm) 164.4 165 130-198
Cystatin C (mg/L) 1.01 0.91 0.38-3.1
Serum creatinine (mg/dL) 0.80 0.9 0.39-1.2
BUN (mg/dL) 15.1 12.9 0-80
Intensive care unit admission (+/-) (No.) 496/182
Amikacin co-administration (+/-) (No.) 45/633
Furosemide co-administration (+/-) (No.) 114/564
Vancomycin daily dose (mg)
   250-1,000 (No.)
  > 1,000-2,000 (No.)
  > 2,000-4,500 (No.)
1,922
59
605
14
2,000 250-4,500
BUN, Blood Urea Nitrogen.
Table 2. Parameter estimates and bootstrap analysis of the final model
Parameters* Estimate (RSE†) Median (95% CI) by Bootstrap‡
CLPOP (L/h)§ 4.90 (1.5%) 4.90 (4.77-5.05)
VPOP (L)§ 46.2 (1.6%) 46.2 (44.9-47.7)
θCLage -0.00420 (18.2%) -0.00427 (-0.00576--0.00276)
θCLTBW 0.00997 (8.8%) 0.00994 (0.00823-0.0116)
θCLSCr -0.322 (17.1%) -0.321 (-0.428--0.212)
θCLcystatin -0.780 (5.3%) -0.776 (-0.850--0.701)
θCLsex -0.150 (13.5%) -0.151 (-0.190--0.107)
θVage 0.00580 (12.3%) 0.00579 (0.00438-0.00715)
θVTBW 0.00661 (15.9%) 0.00665 (0.00437-0.0087)
θVsex -0.119 (20.5%) -0.119 (-0.166--0.0722)
ISV_CL† (%) 24.7 (26.2%) 24.7 (23.0-26.3)
ISV_V† (%) 25.1 (37.3%) 25.0 (21.0-28.4)
Residual variability
   Additional error (mg/L)
   Proportional error†
  
1.40 (12.9%)
6.39% (22.8%)
  
1.39 (0.904-1.70)
6.48% (3.15%-9.25%)
OFV 5316.986 5295.906 (5160-5440)
*CL, clearance; V, volume of distribution; ISV, unexplained intersubject variability; 
OFV, objective function value; CL = CLPOP × (1 + θCLage × [age-57]) × (1 + θCLTBW ×
[TBW-60.8]) × (1 + θCLSCr × [SCr-0.8]) × (Cystatin C/0.91)θCLcystatin, (if female, apply 1+
θCLsex); V = VPOP × (1 + θVage × [age-57]) × (1+ θVTBW × [TBW-60.8]), (if female, apply 
1+θVsex); †Expressed as a coefficient of variation; RSE, % relative standard error of 
the estimate; ‡Statistics from 1,000 bootstrap replicates; CI, confidence interval; 
§Median population value.
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reduced from 44.4% and 28.6% to 24.7% and 25.1%, respective-
ly. When only cystatin C was used as a covariate in the model, 
unexplained ISV of CL was reduced to 31.1%. Plots of model-
predicted versus observed concentrations based on population 
and individual parameter estimates of the final model are shown 
in Fig. 1. The residual error based goodness-of-fit plots (IWRES 
versus individual prediction, conditional weighted residual ver-
sus time, and others) were visually checked and acceptable (fig-
ure not shown). The shrinkage for EBEs and residual errors were 
as follows: shrinkage (EBE_CL) = 5.8%, shrinkage (EBE_V) =  
17.3%, and shrinkage (IWRES) = 48.3%.
Model evaluation
The robustness of the final model was evaluated by a bootstrap 
analysis (1,000 replicates). The final parameter estimates and 
results of the bootstrap procedure are shown in Table 2. The 
population estimates of the final model were very close to the 
median of the nonparametric bootstrap replicates, and all esti-
mates were included within the 95% confidence intervals. NPCs 
of the data exhibited good predictive performance with a slight 
overprediction at the upper limit of the 95th percentile predic-
tion interval (Fig. 2). The population-predicted concentrations 
were unbiased, with an MPE of 4.6% and a precision (estimated 
by the MAPE) of 25.8%. Using individual predicted concentra-
tions, the bias and precision were 0.1% and 5.9%, respectively.
Prediction of vancomycin concentration in various groups 
of patients
Predicted steady-state time-concentration profiles of vancomy-
cin after 1,000 mg q 12 hr administrations were simulated using 
the final model in patients with normal SCr concentration (≤ 1.2 
mg/dL) (Fig. 3). In patients with typical demographic character-
istics (age = 57 yr, TBW = 60.8 kg, male, SCr = 0.8 mg/dL), the 
predicted vancomycin trough concentrations were 2.4-33.8 mg/ 
L (14-fold) for cystatin C concentrations ranging from 0.4 to 3.0 
mg/L. The trough and peak concentrations in the representa-
tive high-CL group (CL = 10.9 L/h and V = 45.7 L by age = 20 yr, 
TBW = 100 kg, male, cystatin C = 0.4 mg/L, and SCr = 0.6 mg/
dL) were 0.4 and 18.7 mg/L, respectively, and those of the low-
CL group (CL = 1.7 L/h and V = 41.8 L by age = 90 yr, TBW = 40 
kg, female, cystatin C = 3.0 mg/L, and SCr = 1.2 mg/dL) were 
85.2 and 107.1 mg/L, respectively, which were 213- and 5.7-fold 
changes, respectively, than those in the high-CL group. Even at 
the same cystatin C concentration of 3.0 mg/L, the low-CL group 
exhibited a 250% higher trough concentration (85.2 mg/L) than 
the typical population group (33.8 mg/L). 
Fig. 1. Goodness of fit evaluated by the plots of (A) population prediction versus observed vancomycin concentration (mg/L) and (B) individual prediction versus observed van-
comycin concentration (mg/L). Solid lines are the linear regression line from the data (thick) or the line of identity (thin).
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Fig. 2. Results of the numerical predictive check. The connected black dots represent 
the ratio of the number of observations that are outside their own prediction intervals 
to the expected number (e.g., 10% of the data are expected to be outside a 90% pre-
diction interval, 5% above and 5% below). The dotted lines represent the 95% confi-
dence intervals for this ratio given the correct model.
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DISCUSSION
In this study, we developed an integrated population PK model 
of vancomycin that quantifies the cystatin C effect as well as sig-
nificant demographic data in adult patients with normal SCr 
concentrations. The model indicates that cystatin C has a close 
relationship with vancomycin CL with an inverse power of -0.78. 
This reciprocal relationship has been reported previously for 
cystatin C and GFR (17, 18). Other continuous demographic 
variables centered on their populzation median values have 
linear relationships within the observed range. Age and SCr 
had negative and TBW had a positive relationship with CL. Fe-
males have 15% lower clearance, which is in line with the Cock-
croft and Gault equation (19).
 The influence of each continuous covariate on PK parame-
ters was calculated by the maximum percent difference of the 
parameter using the marginal or median values from the equa-
tions of the final model. The order of the difference size was as 
follows: for CL, cystatin C (62%) > TBW (34%) > age (17%) > sex 
(15%) > SCr (13%); and for V, TBW (52%) > age (23%) > sex (12%). 
Cystatin C is the most influential factor for vancomycin CL and 
has an approximately 5-fold greater effect than SCr. TBW was 
also an important covariate for both CL and V. As only 33 pa-
tients (4.9%) were clinically obese (body mass index > 30 kg/m2), 
using ideal body weight or lean body weight instead of TBW in 
the population PK analysis did not improve the fitting signifi-
cantly, which was consistent with other studies, and the actual 
TBW is usually recommended for dosage adjustment for van-
comycin TDM (20). Simulation analysis indicated that a 14-fold 
difference in the trough concentrations (2.4-33.8 mg/L) of van-
comycin was observed according to only cystatin C concentra-
tions at the same dosage of vancomycin. Using other demo-
graphic factors together, our model could predict a wider range 
of trough concentrations of 0.4-85.2 (213-fold) in representative 
cases of high- or low-CL patients as expected.
 There was good agreement between the predicted and ob-
served values from a visual exploration. The predictive perfor-
mance of the model, expressed as bias and precision, were less 
than 5 and 30%, respectively, in the population prediction. This 
is clinically acceptable considering the errors from assay and/or 
clinical procedures in routine care settings. The NPC failed only 
at the upper limit of the 95% interval. This means that in some 
cases, very high concentrations mainly consisting of peak con-
centrations were not predicted well. This is possibly due to the 
estimation problem regarding V by a one-compartmental mod-
el. ISV for V was also imprecisely estimated with a standard error 
of 37%. In these sparse data from routine clinical practice, V is 
generally not precisely estimated relative to CL estimation as 
reported previously (21, 22). Limited samples permit only one-
compartment modeling, although two-compartment modeling 
is considered more realistic for vancomycin PK (23, 24). How-
ever, this model can provide results representative of the popu-
lation studied because a large number of patients were analyzed. 
In addition, the treatment outcome of vancomycin is mainly 
correlated to vancomycin trough concentrations, and thus, we 
believe that the application of this model will be possible for 
routine clinical care with minor exceptions at very high concen-
trations.
 The extent of the shrinkage of IWRES was moderate (48%), 
but it is considered acceptable because the observations con-
sisted of sparse routine clinical data. The most problematic situ-
ation of the epsilon shrinkage is model misspecification (25). 
However, the impact of model misspecification was low because 
there was substantial evidence of one-compartmental analysis 
Fig. 3. Predicted steady-state vancomycin concentration during and after the administration of 1,000 mg of vancomycin q 12 hr  when only cystatin C changed in patients with 
typical demographic characteristics (A) and in representative patients with low (CL = 1.7 L/h and V = 41.8 L) or high (C L= 10.9 L/h and V = 45.7 L) vancomycin clearance 
calculated by their covariates (B).
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of vancomycin PK with routine TDM data, and the estimated 
values of PK parameters were similar to those of our model (12, 
21, 26, 27). Moreover, there was similarity in the PK parameters 
across different ethnic groups. We believe that our results can 
be generalized to other ethnic groups, although confirmation is 
needed.
 In linking the pharmacodynamics with the PK of vancomy-
cin, an AUC24/MIC value of at least 400 was proposed for the 
treatment of invasive MRSA in vancomycin practice guidelines 
(20). The AUC24/MIC values of individual patients were ob-
tained using the model with an estimated AUC24 (daily dose di-
vided by CL) and an MIC of 1 mg/L. In total, 362 out of 678 pa-
tients (53.4%) had AUC24/MIC values above the target of 400. 
Trough concentrations (Ctrough) were also predicted, and the 
numbers of patients with Ctrough < 5, 5 - < 20, and ≥ 20 mg/L 
were 154 (22.7%), 465 (68.6%), and 59 (8.7%), respectively. In 
this post hoc analysis, when the Ctrough is higher than 10 mg/L 
(259 patients), the percentage of patients with AUC24/MIC ≥ 400 
was 99.6% (258 out of 259). However, for patients with Ctrough of 
5-10 mg/L, only 39.1% (101/265) of patients achieved the target 
AUC24/MIC, and thus, the possibility of treatment failure is in-
creased in this concentration range. As a surrogate marker to 
predict the target AUC24/MIC, maintaining a Ctrough ≥ 10 mg/L 
would be proposed in this population.
 This is the first study to analyze the actual effect of cystatin C 
by integrated population PK modeling of vancomycin with full 
evaluation of covariates in a large population. Modeling was 
done in assumption-free conditions: no GFR estimation, no cal-
culated demographic factors, and no restriction to steady-state 
concentrations. All covariates had a direct relationship with each 
PK parameter. A large pool of data rendered the estimation er-
rors very small for the population PK parameters and the effects 
of covariates, which were consistently observed in a nonpara-
metric bootstrap analysis.
 Our study has some limitations. First, the model has not been 
evaluated by external data. Although measuring vancomycin 
concentration itself at peak and trough is the best validated pre-
dictor of clinical response and toxicity, we believe the dosing 
guide using our model is applicable if it can reliably predict peak 
and trough concentrations and AUC24/MIC values before the 
initiation of therapy and thus lead to improved treatment out-
comes. To accomplish this, the predictive performance of the 
model should be validated using an external dataset, and the 
treatment outcomes need to be confirmed. Second, the clinical 
utility of the model is limited. It is necessary to further study how 
well the AUC24/MIC values obtained through our model reflect 
the treatment outcome in patients with MRSA bacteremia us-
ing the real MIC values prospectively. It is also necessary to in-
vestigate the difference between the calculated AUC24 based on 
the conventional SCr value and our cystatin C model and clarify 
how these differences affect the determination of vancomycin 
dosage. Third, this model is focusing on the patients with SCr 
≤ 1.2 mg/dL, so its utility to renal impairment patients outside 
this range (about 20% in our internal data) would be limited.
 In conclusion, the population PK model of vancomycin in 
relation to cystatin C was developed for Korean patients. There 
was considerable variability in vancomycin concentrations even 
among normal SCr concentrations. Cystatin C concentrations 
reflect vancomycin CL better than SCr concentrations and play 
a major role in explaining this variability. Measuring cystatin C 
concentrations is recommended for the optimal dosage selec-
tion of vancomycin based upon our population PK model among 
patients with normal SCr concentrations. Furthermore, cystatin 
C would be a good marker for dose adjustment when TDM is 
performed for drugs that are excreted mainly by the kidneys, 
which needs to be confirmed clinically in a prospective study.
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